A Phase 1 interventional study of Pharmacokinetic sampling - AZD9291 and AZD9291 tablet dosing in Healthy Volunteer, sponsored by AstraZeneca. Completed at 2 sites in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-24.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 1, open-label, 2-period fixed sequence design to evaluate the interaction of AZD9291 with omeprazole in approximately 50 healthy, adult male volunteers. Volunteers will receive Treatment A (AZD9291 and omeprazole) in Period 1 and Treatment B (AZD9291 only) in Period 2. The dose of AZD9291 in Period 1 and the dose of AZD9291 in Period 2 will be separated by a washout of at least 21 days (the washout will not be more than 5 weeks). The study will be performed at up to 2 sites in the USA and will assess the effect of omeprazole (proton pump inhibitor) on AZD9291 exposure
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 136 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
For inclusion in the study volunteers must fulfil the following criteria.
Volunteers must not enter the study if any of the following exclusion criteria are fulfilled:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sequential treatments of AZD9291 + omeprazole followed by AZD9291 alone, with a washout period in between.
Procedure: Pharmacokinetic sampling - AZD9291 · Drug: AZD9291 tablet dosing · Drug: Omeprazole tablet dosing · Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550
Blood sampling to measure AZD9291
AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
Omeprzole taken from Days 1 to 5 in Period 1.
Blood samples to measure levels of AZ5140 and AZ7550
AUC of AZD9291
Area under the plasma concentration-time curve from zero to infinity for AZD9291
Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose
Cmax of AZD9291
Rate and extent of absorption of AZD9291 following single oral doses of AZD9291 tablet formulation by assessment of maximum plasma concentration (Cmax).
Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
AUC(0-t)
Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using area under the plasma concentration curve from zero extrapolated to o the time of the last quantifiable concentration, AUC(0-t)
Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
AUC(0-72)
Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using area under the plasma concentration curve from time zero to 72 hours, AUC(0-72)
Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours post AZD9291 dose.
Tmax
Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using time to reach maximum plasma concentration, tmax
Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Tlag
Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using lag time before observation of quantifiable analyte concentrations in plasma, tlag
Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
t(1/2)
Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using the terminal half-life, t(1/2)
Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
λz
Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using the terminal rate constant, λz
Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
CL/F of AZD9291
Assessment of the PK of AZD9291 using the apparent plasma clearance, CL/F
Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Vz/F of AZD9291
Assessment of the PK of AZD9291 using the apparent volume of distribution, Vz/F
Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Cmax of AZ5104 and AZ7550
Assessment of the PK of AZ5104 and AZ7550 (metabolites to AZD9291) using the maximum plasma concentration, Cmax
Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
AUC of AZ5104 and AZ7550
Area under the plasma concentration-time curve from zero to infinity of AZ5104 and AZ7550 (metabolites to AZD9291)
Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Parent to Metabolite Ratios of AZ5104 and AZ7550 Cmax
Assessment of the PK of AZ5104 and AZ7550 Cmax using the parent (AZD9291) to metabolite ratios
Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
Parent to Metabolite Ratios of AZ5104 and AZ7550 AUC
Assessment of the PK of AZ5104 and AZ7550 AUC using the parent (AZD9291) to metabolite ratios
Time frame: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.
First subject enrolled: 3 September 2014 Last Subject Last Visit: 5 January 2015 Study was performed at 2 sites in the USA.
| Milestone | AZD9291 and Omeprazole |
|---|---|
| Started | 68 |
| Completed | 47 |
| Not completed | 21 |
| Withdrew: Exceeding pk limits after period 1 | 11 |
| Withdrew: Protocol violation | 4 |
| Withdrew: Adverse event | 3 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Protocol non-compliance | 2 |
| Milestone | AZD9291 and Omeprazole |
|---|---|
| Started | 47 |
| Completed | 47 |
| Not completed | 0 |
Area under the plasma concentration-time curve from zero to infinity for AZD9291
| nM.h | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| AUC of AZD9291 | 6690 ± 28.8 | 6269 ± 37.0 |
Rate and extent of absorption of AZD9291 following single oral doses of AZD9291 tablet formulation by assessment of maximum plasma concentration (Cmax).
| nM | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| Cmax of AZD9291 | 127.8 ± 26.9 | 126.1 ± 31.0 |
Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using area under the plasma concentration curve from zero extrapolated to o the time of the last quantifiable concentration, AUC(0-t)
| nM.h | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| AZD9291 | 6673 (2340 to 10200) | 6249 (2660 to 14100) |
| AZ5104 | 546.5 (226 to 939) | 539.2 (230 to 1110) |
| AZ7550 | 520.0 (208 to 1010) | 560.0 (300 to 942) |
Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using area under the plasma concentration curve from time zero to 72 hours, AUC(0-72)
| nM.h | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| AZD9291 | 4404 (1710 to 6410) | 4106 (1760 to 7530) |
| AZ5104 | 301.5 (151 to 589) | 304.0 (153 to 540) |
| AZ7550 | 216.5 (82.1 to 398) | 231.3 (100 to 445) |
Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using time to reach maximum plasma concentration, tmax
| h | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| AZD9291 | 6 (5 to 48.08) | 6 (3 to 12.1) |
| AZ5104 | 8 (5 to 72.12) | 7 (4 to 48.05) |
| AZ7550 | 10 (5 to 72.42) | 10 (5 to 71.77) |
Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using lag time before observation of quantifiable analyte concentrations in plasma, tlag
| h | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| AZD9291 | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| AZ5104 | 0.00 (0.00 to 2.00) | 0.00 (0.00 to 1.00) |
| AZ7550 | 0.00 (0.00 to 2.00) | 0.00 (0.00 to 1.00) |
Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using the terminal half-life, t(1/2)
| h | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| AZD9291 | 58.99 (39.2 to 77.1) | 63.60 (52.3 to 80.4) |
| AZ5104 | 51.06 (31.1 to 85.4) | 54.47 (34.5 to 87.7) |
| AZ7550 | 71.34 (47.0 to 106) | 72.16 (48.5 to 102) |
Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using the terminal rate constant, λz
| 1/h | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| AZD9291 | 0.011748 (0.00899 to 0.0177) | 0.010898 (0.00862 to 0.0132) |
| AZ5104 | 0.013577 (0.00812 to 0.0223) | 0.012722 (0.00790 to 0.0201) |
| AZ7550 | 0.009718 (0.00656 to 0.0147) | 0.009606 (0.00677 to 0.0143) |
Assessment of the PK of AZD9291 using the apparent plasma clearance, CL/F
| L/h | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| CL/F of AZD9291 | 23.93 (15.6 to 68.4) | 25.55 (11.3 to 60.1) |
Assessment of the PK of AZD9291 using the apparent volume of distribution, Vz/F
| L | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| Vz/F of AZD9291 | 2037 (1280 to 3870) | 2343 (1250 to 5120) |
Assessment of the PK of AZ5104 and AZ7550 (metabolites to AZD9291) using the maximum plasma concentration, Cmax
| nM | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| AZ5104 | 5.543 ± 26.9 | 5.889 ± 31.0 |
| AZ7550 | 3.913 (1.68 to 7.98) | 4.402 (2.04 to 9.69) |
Area under the plasma concentration-time curve from zero to infinity of AZ5104 and AZ7550 (metabolites to AZD9291)
| nM.h | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| AZ5104 | 556.6 ± 28.8 | 550.7 ± 37.0 |
| AZ7750 | 536.5 (231 to 1020) | 574.9 (309 to 955) |
Assessment of the PK of AZ5104 and AZ7550 Cmax using the parent (AZD9291) to metabolite ratios
| Ratio | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| AZ5104 | 0.04335 (0.0255 to 0.0873) | 0.04671 (0.0293 to 0.0908) |
| AZ7550 | 0.03061 (0.0169 to 0.0530) | 0.03491 (0.0169 to 0.0708) |
Assessment of the PK of AZ5104 and AZ7550 AUC using the parent (AZD9291) to metabolite ratios
| Ratio | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| AZ5104 | 0.08318 (0.0464 to 0.137) | 0.08785 (0.0587 to 0.133) |
| AZ7550 | 0.08019 (0.0334 to 0.152) | 0.09166 (0.0424 to 0.207) |
Collected over AEs collected from the day prior to first dose of treatment (omeprazole) until the follow up visit, approximately 3 months.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AZD9291 and Omeprazole Co-administration | — | 3/68 (4.4%) | 8/68 (11.8%) |
| AZD9291 Alone | — | 0/47 (0%) | 2/47 (4.3%) |
| Event | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| Transaminases increasedInvestigations | 2/68 | 0/47 |
| CholelithiasisHepatobiliary disorders | 1/68 | 0/47 |
| Blood creatine phosphokinase increasedInvestigations | 1/68 | 0/47 |
| Event | AZD9291 and Omeprazole Co-administration | AZD9291 Alone |
|---|---|---|
| HeadacheNervous system disorders | 5/68 | 0/47 |
| Blood creatine phosphokinase increasedInvestigations | 3/68 | 2/47 |
| Age, Continuous(Years) | AZD9291 and Omeprazole |
|---|---|
| Mean | 34.0 ± 11.08 |
| Sex: Female, Male(Participants) | AZD9291 and Omeprazole |
|---|---|
| Female | 0 |
| Male | 68 |
The record gives a start of Sep 2014, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osimertinib